Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

The Nasdaq Health Care subindex is down nearly 10% from its high in early September, leaving investors wondering if now would be the time to “buy the dip”; especially after Merck's big news this morning that sent shares of Moderna, Novavax, and BioNTech crashing down. Michael Bapis' remarks on CNBC's “Trading Nation” According to Vios […] The post Traders share their outlook on the health care space after Merck's big news appeared first on Invezz.

Traders share their outlook on the health care space after Merck's big news

The blue-chip drugmaker reported positive results for its oral COVID-19 treatment, developed alongside Ridgeback Biotherapeutics.

Stock Market Today: Dow Jumps 482 Points on Promising Merck Data

4:05 pm: US equities close higher on COVID-19 pill breakthrough US stocks closed higher to mark the start of October trading as news of a new oral treatment for COVID-19 boosted shares of companies tied to the economic recovery. Shares of Dow member Merck jumped 9% after the drugmaker and Ridgeback Biotherapeutics said their oral antiviral treatment for COVID reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases.

US stocks close higher on Merck's new COVID-19 oral treatment announcement

US stocks still closed the week lower on Friday, but well off the lows sparked by higher interest rates and rising inflation.

Dow spikes 482 points after Merck's COVID-19 pill boosts recovery optimism

The pharmaceutical giant soared 10% on Friday, helping the Dow reverse massive losses from its down week.

Dow Rallies Nearly 500 Points After Merck's Covid Pill ‘Injects Life' Into Slumping Stocks

Even so, they're taking a big dive Friday.

Merck Shouldn't Matter to the Nasdaq's Vaccine Stocks

On Friday, Merck & Co Inc. (NYSE:MRK) shares spiked more than 9% after announcing positive developments in its covid-19 pill. The company with Ridgeback Biotherapeutics are developing an oral antiviral medicine, molnupiravir for the treatment of covid-19.

Merck stock price forecast for Q4 2021 amid positive data on a covid-19 pill

Moderna

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.

Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector

Acceleron Pharma

Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag. Related:   Merck Seals Acceleron Pharma Deal For $180/Share: Highlights.

Activist Investor Thinks Merck Undervalues Acceleron Buy

Regeneron Pharmaceuticals

Core PCE Inflation Stays at Record-High in August.

Core PCE Inflation Stays at Record-High in August

Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.

Merck (MRK) Develops Pill to Lessen Covid Symptoms

The new quarter appears to be starting off on a slightly higher note as futures are pointing to a positive opening. Stocks are being helped by the drug company Merck (NYSE: MRK) and Ridgeback Biotherapeutics which are partnering on an experimental COVID-19 pill that has new data showing success in helping to prevent high-risk people avoid serious illness and death.

Merck Announcement Helps Prompt Positive Pre-Market Price Moves

Merck cheered investors and healthcare experts alike on Friday with the news that its COVID-19 antiviral cut the risk of hospitalization or death by roughly half in a late-stage trial, and could become a powerful tool in reining in the pandemic.

Coronavirus Update: Merck cheers health experts with news antiviral cut risk of hospitalization and death by half in trial, and could become powerful tool in combating COVID-19

Merck (MRK) stock is taking off on Friday thanks to positive news from a clinical trial for treating COVID-19 with molnupiravir. The post Merck News: The ‘Game-Changer' Making MRK Stock the No.

Merck News: The ‘Game-Changer' Making MRK Stock the No. 1 Trending Ticker Today

Merck & Co Inc, the US drugs giant, said clinical trials of its antiviral drug molnupiravir show it can significantly cut the risk of hospitalisation or death from Covid-19. The pharmaceutical group, a member of the blue-chip Dow Jones index, and partner Ridgeback Biotherapeutics, which first developed the drug, said early results from a trial of molnupiravir showed that 7.3% of patients on the drug had died or been hospitalised, compared to 14.1% of those receiving a placebo.

Antiviral drug from Merck slashes risk of Covid hospitalization or death

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.

Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio

Merck & Co Inc (NYSE: MRK) reported interim results for the clinical trial of its experimental COVID-19 pill on Friday that showed Molnupiravir to be effective in reducing hospitalisation and deaths by about 50% for patients at risk of severe disease. The oral drug was developed in collaboration with Ridgeback Biotherapeutics.

Dr Gottlieb on Merck's oral COVID-19 drug: ‘it's a profound game changer'

Why Merck Stock Is Heating Up Today

Merck already has a deal to supply 1.7 million courses of antiviral pill molnupiravir to the US government.

Merck jumps 10% as the drugmaker says its antiviral pill cuts the risk of hospitalizations and deaths in COVID patients

Merck & Co Inc (NYSE: MRK) is trading higher Friday after the company and Ridgeback announced investigational oral antiviral molnupiravir reduced risk of hospitalization or death by about 50% versus the placebo for patients with mild to moderate COVID-19 in Phase 3 interim analysis. Merck said it plans to submit an application for Emergency Use Authorization to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.

Why Merck Shares Are Surging Higher Today

Merck plans to apply for emergency approval of molnupiravir, a pill that cut mild to moderate COVID-19 hospitalizations by roughly 50 percent.

Merck to seek emergency US approval of oral COVID treatment

Merck said it would seek emergency approval for the first antiviral pill to treat Covid-19 off the back of the study.

Merck Says Its Antiviral Pill Cuts Risk Of Covid Hospitalizations, Deaths By Half

If authorized, Merck and Ridgeback's drug, Molnupiravir, would be the first antiviral pill designed to treat COVID-19 specifically.

Merck will ask regulators to authorize the first antiviral pill designed to treat COVID-19, after a trial found it halved the risk of hospitalization or death

Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have announced data from a planned interim analysis of Phase 3 MOVe-OUT trial of molnupiravir (MK-4482, EIDD-2801) from 775 COVID-19 patients. Related:   Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show.

Merck COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%

Merck shares MRK, +0.03% jumped 3.5% in premarket trade Friday, after the company said the oral antiviral it developed as a treatment for COVID-19 with partner Ridgeback Biotherapeutics reduced the risk of hospitalization or death in at risk adult patients with mild-to-moderate COVID by about 50% in an interim analysis of data from a Phase 3 trial. Some 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of patients given a placebo.

News for Merck Stock (MRK)